Instructions for Rinzasip
Instructions for use Rinzasip:
Form of release Composition Pharmaco-therapeutic group Pharmacological properties Overdose Indications for use Method of application Contraindications Side effects Special instructions Drug interaction Conditions of dispensing from pharmacies and shelf life
Release form
Powder for preparation of oral solution from light yellow to yellow color, with white and yellow blotches, with lemon flavor.
5 g - sachet (10) - cardboard packs.
Structure Rinzasip:
1 sachet (5 g)
paracetamol 750 mg
caffeine 30 mg
pheniramine maleate 20 mg
phenylephrine hydrochloride 10 mg
Excipients: anhydrous citric acid, sodium saccharin, sodium citrate, sucrose, quinoline yellow dye, lemon flavor.
Pharmaco-therapeutic group Rinzasip:
A remedy for eliminating the symptoms of acute respiratory infections and "colds" (non-narcotic analgesic + vasoconstrictor + vitamin).
Pharmacological properties Rinzasip:
Combined drug used for colds.
Paracetamol - an analgesic-antipyretic, reduces pain associated with colds - sore throat, headache, muscle and joint pain, reduces high body temperature.
Phenylephrine is a sympathomimetic, has a vasoconstrictor effect on peripheral vessels, reduces edema and hyperemia of the mucous membrane of the upper respiratory tract and sinuses.
Pheniramine - a blocker of histamine H1 receptors, has an antiallergic effect: eliminates itching (including eyes, nose), swelling and hyperemia of the mucous membranes of the nasal cavity, nasopharynx and sinuses, reduces exudation.
Caffeine has a stimulating effect on the central nervous system, which leads to a decrease in fatigue and drowsiness and to an increase in mental and physical performance.
Overdose Rinzasip:
Overdose symptoms due to the effects of paracetamol appear when the drug Rinzasip is taken in a dose corresponding to 10-15 g of paracetamol.
Symptoms: pallor of the skin, anorexia, nausea, vomiting, increased activity of hepatic transaminases, hepatonecrosis, liver failure (increased prothrombin time).
Treatment: gastric lavage, inside - activated carbon; symptomatic therapy, the introduction of methionine 8-9 hours after the overdose and N-acetylcysteine after 12 hours.
Indications for use Rinzasip:
- Symptomatic therapy (to reduce pain, fever and rhinorrhea):
- flu;
- SARS and other colds.
Mode of application
Adults and children over 15 years of age are prescribed 1 sachet 3-4 times / day with intervals between doses of at least 4-6 hours. The maximum daily dose is 4 sachets. The course of treatment should not exceed 5 days.
The drug is taken 1-2 hours after meals with plenty of liquid.
The content of 1 sachet is dissolved in 1 glass of hot water (stirred until completely dissolved). You can add sugar or honey.
Contraindications Rinzasip:
concomitant use of tricyclic antidepressants, MAO inhibitors, beta-blockers;
pregnancy;
lactation (breastfeeding); Rinzasip
children and adolescents up to 15 years old;
the simultaneous administration of other medicines, which include the active substances of the drug Rinzasip;
hypersensitivity to paracetamol and other components of the drug.
The drug is prescribed with caution for severe atherosclerosis of the coronary arteries, arterial hypertension, thyrotoxicosis, pheochromocytoma, patients with diabetes mellitus, bronchial asthma, chronic obstructive pulmonary disease, deficiency of glucose-6-phosphate dehydrogenase, blood diseases, patients with hereditary hyperbilirubine syndrome Johnson and Rotor), with hepatic and / or renal failure, angle-closure glaucoma, prostatic hyperplasia.
Side effects
From the side of the central nervous system: dizziness, sleep disturbance, hyperexcitability, mydriasis, increased intraocular pressure, paresis of accommodation.
From the side of the cardiovascular system: increased blood pressure, tachycardia.
From the digestive system: nausea, epigastric pain, dry mouth, hepatotoxic effect.
From the hematopoietic system: anemia, thrombocytopenia, agranulocytosis, hemolytic anemia, aplastic anemia, methemoglobinemia, pancytopenia.
From the urinary system: urinary retention, nephrotoxic effect (papillary necrosis).
Allergic reactions: skin rash, itching, urticaria, angioedema.
Others: broncho-obstructive syndrome.
special instructions Rinzasip:
During the use of the drug Rinzasip, you should refrain from drinking alcohol, sleeping pills or anxiolytic drugs.
You can not simultaneously use drugs containing paracetamol.
The patient should be warned about the need to consult a doctor if the condition does not improve after 3-5 days of taking the drug.
Influence on the ability to drive vehicles and use mechanisms
During the use of the drug, care should be taken when engaging in potentially hazardous activities that require increased attention and speed of psychomotor reactions.
Drug interactions Rinzasip:
When used together, Rinzasip enhances the effects of MAO inhibitors, sedatives, ethanol.
When used together with Rinzasip, antidepressants, antiparkinsonian drugs, antipsychotic drugs, phenothiazine derivatives increase the risk of urinary retention, dry mouth, and constipation. Rinzasip
When used together, GCS increases the risk of developing glaucoma.
Paracetamol reduces the effectiveness of concomitantly used diuretics.
Tricyclic antidepressants enhance the adrenomimetic effect of phenylephrine; administration with halothane increases the risk of ventricular arrhythmia.
When used together, Rinsasip reduces the antihypertensive effect of guanethidine, which in turn enhances the alpha-adrenergic stimulating effect of phenylephrine.
With the simultaneous use of Rinzasip with barbiturates, diphenin, carbamazepine, rifampicin and other inducers of microsomal liver enzymes, the risk of developing the hepatotoxic effect of paracetamol increases.